Core Insights - OssDsign has successfully treated 10,000 patients with its innovative nanosynthetic bone graft, OssDsign Catalyst, in the US market [1][2] - The product has shown rapid and robust bone formation, even in poorly vascularized environments, and has significantly penetrated the American orthobiologics market since its launch in August 2021 [2][3] - The usage of OssDsign Catalyst has doubled from 5,000 patients reported last year, indicating strong demand from American surgeons and hospitals [3] Company Overview - Karolinska Development AB is a Nordic life sciences investment company focused on identifying and developing breakthrough medical innovations [4][5] - The company has a portfolio of eleven companies targeting innovative treatments for serious diseases, supported by experienced management teams and a strong global network [6]